A small biotech boasting a technology aimed at targeting difficult-to-drug glycans and a big pharma firm continuing to make inroads in the orphan disease space came together in an early stage deal to develop small molecules against lysosomal storage disorders (LSDs) such as mucopolysaccharidoses.